Dr. Davide Corti obtained his Ph.D. in Immunology at the University of Bern, followed by postdoctoral training in Antonio Lanzavecchia’s laboratory at the Institute for Research in Biomedicine, where he further developed and optimized two methods for the isolation of human monoclonal antibodies out of memory B cells and plasma cells (Cellclone technologies).
As Chief Scientific Officer at Humabs, he led a research group to isolate monoclonal antibodies against multiple infectious disease viral and bacterial agents. Dr. Corti collaborated with MedImmune on the isolation of human antibodies against multiple target pathogens including Rhinovirus, Influenza B, Klebsiella and Staphylococcus. His teams’ efforts to date have generated three clinical stage candidates, MEDI8852 targeting Influenza A, mAb114 targeting Ebola virus and anti-CMV antibodies.
Dr. Corti has published more than 140 peer reviewed journal articles and holds 30 patents. He is now SVP at Humabs BioMed, a subsidiary of Vir Biotechnology, leading Antibody Research.